Cargando…
The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy
Fosfomycin in intravenous (IV) formulation has re-emerged as a valuable tool in the treatment of multi-drug resistant (MDR) and extensively drug-resistant (XDR) infections because of its broad spectrum of antibacterial action and pharmacokinetic characteristics. This retrospective study aimed to eva...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295113/ https://www.ncbi.nlm.nih.gov/pubmed/37370290 http://dx.doi.org/10.3390/antibiotics12060971 |
_version_ | 1785063343127527424 |
---|---|
author | Anastasia, Antonio Bonura, Silvia Rubino, Raffaella Giammanco, Giovanni Maurizio Miccichè, Irene Di Pace, Maria Rita Colomba, Claudia Cascio, Antonio |
author_facet | Anastasia, Antonio Bonura, Silvia Rubino, Raffaella Giammanco, Giovanni Maurizio Miccichè, Irene Di Pace, Maria Rita Colomba, Claudia Cascio, Antonio |
author_sort | Anastasia, Antonio |
collection | PubMed |
description | Fosfomycin in intravenous (IV) formulation has re-emerged as a valuable tool in the treatment of multi-drug resistant (MDR) and extensively drug-resistant (XDR) infections because of its broad spectrum of antibacterial action and pharmacokinetic characteristics. This retrospective study aimed to evaluate how fosfomycin was used in patients admitted to the Polyclinic of Palermo between January 2017 and July 2022. Clinical indications, therapeutic associations, clinical outcomes, and any side effects were analyzed. Intravenous fosfomycin was used in 343 patients, 63% male, with a mean age of 68 years (range 15–95). Urinary tract infections (UTIs) and hospital-acquired pneumonia (HAP) were the main indications for treatment (19% and 18% of the total cases, respectively), followed by skin and soft tissue infections and sepsis. IV fosfomycin was administered in combination with other antibacterial agents, the most common of which were ceftazidime/avibactam (35%), meropenem (17%), and colistin (14%). Nineteen patients received it as monotherapy for UTIs. About 66% had resolution of the infectious process with clinical remission (cure or discharge). Electrolyte disturbances occurred in 2.6% and gastrointestinal symptoms occurred in 2.9%. The data showed that IV fosfomycin is a safe and effective therapeutic option in the treatment of infections with multidrug-resistant microorganisms. |
format | Online Article Text |
id | pubmed-10295113 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102951132023-06-28 The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy Anastasia, Antonio Bonura, Silvia Rubino, Raffaella Giammanco, Giovanni Maurizio Miccichè, Irene Di Pace, Maria Rita Colomba, Claudia Cascio, Antonio Antibiotics (Basel) Article Fosfomycin in intravenous (IV) formulation has re-emerged as a valuable tool in the treatment of multi-drug resistant (MDR) and extensively drug-resistant (XDR) infections because of its broad spectrum of antibacterial action and pharmacokinetic characteristics. This retrospective study aimed to evaluate how fosfomycin was used in patients admitted to the Polyclinic of Palermo between January 2017 and July 2022. Clinical indications, therapeutic associations, clinical outcomes, and any side effects were analyzed. Intravenous fosfomycin was used in 343 patients, 63% male, with a mean age of 68 years (range 15–95). Urinary tract infections (UTIs) and hospital-acquired pneumonia (HAP) were the main indications for treatment (19% and 18% of the total cases, respectively), followed by skin and soft tissue infections and sepsis. IV fosfomycin was administered in combination with other antibacterial agents, the most common of which were ceftazidime/avibactam (35%), meropenem (17%), and colistin (14%). Nineteen patients received it as monotherapy for UTIs. About 66% had resolution of the infectious process with clinical remission (cure or discharge). Electrolyte disturbances occurred in 2.6% and gastrointestinal symptoms occurred in 2.9%. The data showed that IV fosfomycin is a safe and effective therapeutic option in the treatment of infections with multidrug-resistant microorganisms. MDPI 2023-05-27 /pmc/articles/PMC10295113/ /pubmed/37370290 http://dx.doi.org/10.3390/antibiotics12060971 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Anastasia, Antonio Bonura, Silvia Rubino, Raffaella Giammanco, Giovanni Maurizio Miccichè, Irene Di Pace, Maria Rita Colomba, Claudia Cascio, Antonio The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy |
title | The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy |
title_full | The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy |
title_fullStr | The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy |
title_full_unstemmed | The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy |
title_short | The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy |
title_sort | use of intravenous fosfomycin in clinical practice: a 5-year retrospective study in a tertiary hospital in italy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295113/ https://www.ncbi.nlm.nih.gov/pubmed/37370290 http://dx.doi.org/10.3390/antibiotics12060971 |
work_keys_str_mv | AT anastasiaantonio theuseofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly AT bonurasilvia theuseofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly AT rubinoraffaella theuseofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly AT giammancogiovannimaurizio theuseofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly AT miccicheirene theuseofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly AT dipacemariarita theuseofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly AT colombaclaudia theuseofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly AT cascioantonio theuseofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly AT anastasiaantonio useofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly AT bonurasilvia useofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly AT rubinoraffaella useofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly AT giammancogiovannimaurizio useofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly AT miccicheirene useofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly AT dipacemariarita useofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly AT colombaclaudia useofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly AT cascioantonio useofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly |